A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Catherine LiuHenry F Chambers

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections have become a major public health problem in both the community and hospitals. Few studies have characterized the incidence and clonal composition of disease-causing strains in an entire population. Our objective was to perform a population-based survey of the clinical and molecular epidemiology of MRSA disease in San Francisco, California. We prospectively collected 3985 MRSA isolates and associated clinical and demographic information over a 12-month period (2004-2005) at 9 San Francisco-area medical centers. A random sample of 801 isolates was selected for molecular analysis. The annual incidence of community-onset MRSA disease among San Francisco residents was 316 cases per 100,000 population, compared with 31 cases per 100,000 population for hospital-onset disease. Persons who were aged 35-44 years, were men, and were black had the highest incidence of community-onset disease. The USA300 MRSA clone accounted for 234 cases of community-onset disease and 15 cases of hospital-onset disease per 100,000 population, constituting an estimated 78.5% and 43.4% of all cases of MRSA disease, respectively. Patients with community-onset USA300 MRSA versus non-USA300 MRSA dis...Continue Reading

References

Mar 5, 1998·JAMA : the Journal of the American Medical Association·B C HeroldR S Daum
Oct 19, 1999·Journal of Clinical Microbiology·B ShopsinB N Kreiswirth
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E J GorakJ D Brown
Sep 18, 2001·JAMA : the Journal of the American Medical Association·A V GroomJ E Cheek
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield
Jun 16, 2004·Current Opinion in Microbiology·Edward J Feil, Mark C Enright
Jun 18, 2004·Emerging Infectious Diseases·Craig E ZindermanBruce K Bohnker
Oct 23, 2004·The Journal of Infectious Diseases·Heather A CarletonFrançoise Perdreau-Remington
Feb 24, 2005·Annals of Emergency Medicine·Bradley W FrazeeFrancoise Perdreau-Remington
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Apr 28, 2005·The Lancet Infectious Diseases·Nicola ZetolaWilliam R Bishai
Jul 21, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Todd Weber
Dec 2, 2005·Emerging Infectious Diseases·Jessica M BuckRuth Lynfield
Feb 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ulrich SeyboldHenry M Blumberg
Aug 18, 2006·The New England Journal of Medicine·Gregory J MoranUNKNOWN EMERGEncy ID Net Study Group
Oct 31, 2006·The American Journal of Medicine·Nancy F CrumKevin L Russell
Nov 23, 2006·Antimicrobial Agents and Chemotherapy·John D SzumowskiKenneth H Mayer
Mar 1, 2007·Emerging Infectious Diseases·R Monina KlevensUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Jun 8, 2007·Emerging Infectious Diseases·Christopher J GraberHenry F Chambers
Jan 29, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Loren G Miller, Binh An Diep

❮ Previous
Next ❯

Citations

Nov 15, 2011·Seminars in Immunopathology·Brad Spellberg, Robert Daum
Nov 15, 2011·Seminars in Immunopathology·Kevin M Rigby, Frank R DeLeo
Feb 15, 2012·International Journal of Clinical Pharmacy·Maria SwartlingB Joseph Guglielmo
Mar 9, 2010·Lancet·Frank R DeLeoHenry F Chambers
Aug 15, 2009·Nature Reviews. Microbiology·Henry F Chambers, Frank R Deleo
Nov 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen W BoucherJohn Bartlett
May 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeffrey S GerberTheoklis E Zaoutis
Dec 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert S Daum, Brad Spellberg
Jun 7, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pierre TattevinBinh An Diep
Dec 9, 2010·The Journal of Antimicrobial Chemotherapy·Robert C Moellering
Apr 24, 2012·The Journal of Antimicrobial Chemotherapy·David J HetemMartin C J Bootsma
Aug 30, 2008·The Pediatric Infectious Disease Journal·Sheldon L Kaplan
Apr 27, 2011·Pediatric Dermatology·Jeffrey L SugarmanIlona J Frieden
Mar 11, 2009·Antimicrobial Agents and Chemotherapy·Jamese J HilliardDarren Abbanat
Nov 14, 2012·Antimicrobial Agents and Chemotherapy·Stephanie A FritzCarey-Ann D Burnham
Mar 17, 2010·Antimicrobial Agents and Chemotherapy·Andrew E SimorUNKNOWN Canadian Nosocomial Infection Surveillance Program
Nov 26, 2011·Journal of Clinical Microbiology·Sam BoundyGordon L Archer
Sep 17, 2010·Journal of Clinical Microbiology·Barbara Juliane HolzknechtOlafur Gudlaugsson
Oct 26, 2012·Interdisciplinary Perspectives on Infectious Diseases·Axel Dalhoff
Sep 5, 2009·The Journal of Clinical Investigation·Frank R DeLeo, Henry F Chambers
Feb 5, 2009·Pediatric Research·George Y Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.